- Home
- ADCT vs CYRX Comparison
ADCT vs CYRX Comparison
Compare ADCT & CYRX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ADCT
- CYRX
- Stock Information
- Founded
- ADCT 2011
- CYRX 1999
- Country
- ADCT Switzerland
- CYRX United States
- Employees
- ADCT N/A
- CYRX N/A
- Industry
- ADCT Biotechnology: Pharmaceutical Preparations
- CYRX Biotechnology: Pharmaceutical Preparations
- Sector
- ADCT Health Care
- CYRX Health Care
- Exchange
- ADCT Nasdaq
- CYRX Nasdaq
- Market Cap
- ADCT 454.5M
- CYRX 438.7M
- IPO Year
- ADCT 2020
- CYRX N/A
- Fundamental
- Price
- ADCT $4.40
- CYRX $9.63
- Analyst Decision
- ADCT Strong Buy
- CYRX Strong Buy
- Analyst Count
- ADCT 6
- CYRX 9
- Target Price
- ADCT $7.60
- CYRX $12.83
- AVG Volume (30 Days)
- ADCT 759.6K
- CYRX 690.3K
- Earning Date
- ADCT 11-10-2025
- CYRX 11-04-2025
- Dividend Yield
- ADCT N/A
- CYRX N/A
- EPS Growth
- ADCT N/A
- CYRX N/A
- EPS
- ADCT N/A
- CYRX 1.27
- Revenue
- ADCT $75,209,000.00
- CYRX $243,795,000.00
- Revenue This Year
- ADCT $11.78
- CYRX N/A
- Revenue Next Year
- ADCT $4.83
- CYRX $9.20
- P/E Ratio
- ADCT N/A
- CYRX $7.60
- Revenue Growth
- ADCT 6.35
- CYRX 41.27
- 52 Week Low
- ADCT $1.05
- CYRX $4.58
- 52 Week High
- ADCT $4.80
- CYRX $11.44
- Technical
- Relative Strength Index (RSI)
- ADCT 58.45
- CYRX 56.67
- Support Level
- ADCT $3.95
- CYRX $8.15
- Resistance Level
- ADCT $4.29
- CYRX $9.29
- Average True Range (ATR)
- ADCT 0.28
- CYRX 0.41
- MACD
- ADCT 0.03
- CYRX 0.14
- Stochastic Oscillator
- ADCT 89.02
- CYRX 93.28
About ADCT ADC Therapeutics SA
ADC Therapeutics SA is a commercial-stage oncology-focused biotechnology company. It is involved in the development of antibody-drug conjugates for patients suffering from hematological malignancies and solid tumors. The company's FDA-approved and marketed product, ZYNLONTA (loncastuximab tesirine), is a CD19-directed antibody and alkylating agent conjugate indicated for the treatment of adult patients with relapsed or refractory large B-cell lymphoma after two or more lines of systemic therapy. In addition, it also has various other product candidates in its pipeline, such as ADCT-602, Claudin-6, PSMA, NaPi2b, and ASCT2. Geographically, the company generates maximum revenue from the United States, followed by Europe, the Middle East and Africa (EMEA).
About CYRX CryoPort Inc.
CryoPort Inc is a leader serving the life sciences industry as a provider of integrated temperature-controlled supply chain solutions supporting the life sciences in the biopharma/pharma, animal health, and reproductive medicine markets. It operates in two reportable segments: Life Sciences Services and Life Sciences Products. Geographically the company operates in the Americas, Europe, the Middle East and Africa (EMEA), and Asia Pacific (APAC), generating a majority of its revenue from the Americas.